Development of nucleic acid drugs for neurological disorders

Current Topics in Medicinal Chemistry

Volumn 12, Issue 15, 2012, Pages 1621-1629

  Shimamura, Munehisa ^a   Sato, Naoyuki ^b   Nakagami, Hironori ^a   Taniyama, Yoshiaki ^b   Morishita, Ryuichi ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer disease; Cerebral ischemia; Diabetic neuropathy; DNA vaccine; Multiple sclerosis; NF B decoy; Nucleic acid drug; Plasmid DNA

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; ATORVASTATIN; BHT 3009; CENTRAL NERVOUS SYSTEM AGENTS; DNA VACCINE; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NUCLEAR FACTOR KAPPA B DECOY; PERFLUBUTANE; PERFLUTREN; PLASMID DNA; RECOMBINANT SCATTER FACTOR; RECOMBINANT VASCULOTROPIN; SCATTER FACTOR; SHU 508; SONOVUE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1;

ALZHEIMER DISEASE; ANGIOGENESIS; AUTOIMMUNE DISEASE; BLOOD FLOW; BRAIN ARTERY ANEURYSM; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BREAST CANCER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COLON CARCINOMA; DIABETIC NEUROPATHY; DIABETIC PATIENT; DNA IMMUNIZATION; DRUG SYNTHESIS; ENCEPHALITIS; GENE EXPRESSION; GENE GUN; GENE GUN IMMUNIZATION; GENE TRANSFER; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LEWIS CARCINOMA; MELANOMA; MICROANGIOPATHY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL (TOPIC); POLYNEUROPATHY; PROTEIN EXPRESSION; REVIEW; RODENT; STREPTOZOCIN DIABETES; TISSUE REGENERATION; TRANSGENE; VISUAL ANALOG SCALE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; NERVOUS SYSTEM DISEASES; OLIGODEOXYRIBONUCLEOTIDES; VACCINES, DNA;

EID: 84867535779     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612803531405     Document Type: Review

References (83)

1. Price, S.A.; Dent, C.; Duran-Jimenez, B.; Liang, Y.; Zhang, L.; Rebar, E.J. Gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy. Diabetes, 2006, 55, 1847-54.
2. Isner, J.M.; Ropper, A.; Hirst, K. VEGF gene transfer for diabetic neuropathy. Hum. Gene. Ther., 2001, 12, 1593-1594.
3. Yoshimura, S.; Morishita, R.; Hayashi, K.; Kokuzawa, J.; Aoki, M.; Matsumoto, K. Gene transfer of hepatocyte growth factor to subarachnoid space in cerebral hypoperfusion model. Hypertension. 2002, 39, 1028-1034.
4. Hayashi, K.; Morishita, R.; Nakagami, H.; Yoshimura, S.; Hara, A.; Matsumoto, K. Gene therapy for preventing neuronal death using hepatocyte growth factor: in vivo gene transfer of HGF to subarachnoid space prevents delayed neuronal death in gerbil hippocampal CA1 neurons. Gene Ther., 2001, 8, 1167-1173.
5. Ropper, A.H.; Gorson, K.C.; Gooch, C.L. Weinberg, D.H.; Pieczek, A.; Ware, J.H. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol., 2009, 65, 386-393.
6. Carlsson, M.; Osman, N.F.; Ursell, P.C.; Martin, A.J.; Saeed, M. Quantitative MR measurements of regional and global left ventricular function and strain after intramyocardial transfer of VM202 into infarcted swine myocardium. Am. J. Physiol. Heart Circ. Physiol., 2008, 295, H522-532.
7. Nakagami, H.; Tomita, N.; Kaneda, Y.; Ogihara, T.; Morishita, R. Anti-oxidant gene therapy by NF kappa B decoy oligodeoxynucleotide. Curr. Pharm. Biotechnol., 2006, 7, 95-100.
8. Ueno, T.; Sawa, Y.; Kitagawa-Sakakida, S.; Nishimura, M.; Morishita, R.; Kaneda, Y. Nuclear factor-kappa B decoy attenuates neuronal damage after global brain ischemia: a future strategy for brain protection during circulatory arrest. J. Thorac. Cardiovasc. Surg., 2001, 122, 720-727.
9. Aoki, T.; Kataoka, H.; Shimamura, M.; Nakagami, H.; Wakayama, K.; Moriwaki, T. NF-kappaB is a key mediator of cerebral aneurysm formation. Circulation, 2007, 116, 2830-2840.
10. Coban, C.; Koyama, S.; Takeshita, F.; Akira, S.; Ishii, K.J. Molecular and cellular mechanisms of DNA vaccines. Hum. Vaccin., 2008, 4, 453-456.
11. Qu, B.; Rosenberg, R.N.; Li, L.; Boyer, P.J.; Johnston, S.A. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol., 2004, 61, 1859-1864.
12. Movsesyan, N.; Ghochikyan, A.; Mkrtichyan, M.; Petrushina, I.; Davtyan, H.; Olkhanud, P.B. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One, 2008, 3, e2124.
13. Qu, B.; Boyer, P.J.; Johnston, S.A.; Hynan, L.S.; Rosenberg, R. N. Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J. Neurol. Sci., 2006, 244, 151-158.
14. Fissolo, N.; Montalban, X.; Comabella, M. DNA-based vaccines for multiple sclerosis: Current status and future directions. Clin. Immunol., 2012, 142(1), 76-83.
15. Lobell, A.; Weissert, R.; Storch, M.K.; Svanholm, C.; de Graaf, K.L.; Lassmann, H. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J. Exp. Med., 1998, 187, 1543-1548.
16. Weissert, R.; Lobell, A.; de Graaf, K.L.; Eltayeb, S.Y.; Andersson, R.; Olsson, T. Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen. Proc. Natl. Acad. Sci. U S A, 2000, 97, 1689-1694.
17. Lobell, A.; Weissert, R.; Eltayeb, S.; de Graaf, K.L.; Wefer, J.; Storch, M.K. Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response. J. Immunol., 2003, 170, 1806-1813.
18. Ferrara, N.; Alitalo, K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med., 1999, 5, 1359-1364.
19. Rosenstein, J.M.; Krum, J.M. New roles for VEGF in nervous tissue--beyond blood vessels. Exp. Neurol., 2004, 187, 246-253.
20. Schratzberger, P.; Walter, D.H.; Rittig, K.; Bahlmann, F.H.; Pola, R.; Curry, C. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J. Clin. Invest., 2001, 107, 1083-1092.
21. Murakami, T.; Arai, M.; Sunada, Y.; Nakamura, A. VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice. J. Gene Med., 2006, 8, 773-781.
22. Nakamura, T.; Nawa, K.; Ichihara, A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem. Biophys. Res. Commun., 1984, 122, 1450-1459.
23. Nakamura, T.; Nishizawa, T.; Hagiya, M.; Seki, T.; Shimonishi, M.; Sugimura, A. Molecular cloning and expression of human hepatocyte growth factor. Nature, 1989, 342, 440-443.
24. Honda, S.; Kagoshima, M.; Wanaka, A.; Tohyama, M.; Matsumoto, K.; Nakamura, T. Localization and functional coupling of HGF and c-Met/HGF receptor in rat brain: implication as neurotrophic factor. Brain Res. Mol. Brain Res., 1995, 32, 197-210.
25. Jung, W.; Castren, E.; Odenthal, M.; Vande Woude, G.F.; Ishii, T.; Dienes, H.P. Expression and functional interaction of hepatocyte growth factor-scatter factor and its receptor c-met in mammalian brain. J. Cell Biol., 1994, 126, 485-494.
26. Zhang, L.; Himi, T.; Morita, I.; Murota, S. Hepatocyte growth factor protects cultured rat cerebellar granule neurons from apoptosis via the phosphatidylinositol-3 kinase/Akt pathway. J. Neurosci. Res., 2000, 59, 489-496.
27. Hossain, M.A.; Russell, J.C.; Gomez, R.; Laterra, J. Neuroprotection by scatter factor/hepatocyte growth factor and FGF-1 in cerebellar granule neurons is phosphatidylinositol 3-kinase/aktdependent and MAPK/CREB-independent. J. Neurochem., 2002, 81, 365-378.
28. Koike, H.; Morishita, R.; Iguchi, S.; Aoki, M.; Matsumoto, K.; Nakamura, T. Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene. FASEB J., 2003, 17, 779-781.
29. Kato, N.; Nemoto, K.; Nakanishi, K.; Morishita, R.; Kaneda, Y.; Uenoyama, M. Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats. Diabetes, 2005, 54, 846-854.
30. Saeed, M.; Martin, A.; Ursell, P.; Do, L.; Bucknor, M.; Higgins, C.B. MR assessment of myocardial perfusion, viability, and function after intramyocardial transfer of VM202, a new plasmid human hepatocyte growth factor in ischemic swine myocardium. Radiology, 2008, 249, 107-118.
31. Miyazawa, T.; Matsumoto, K.; Ohmichi, H.; Katoh, H.; Yamashima, T.; Nakamura, T. Protection of hippocampal neurons from ischemia-induced delayed neuronal death by hepatocyte growth factor: a novel neurotrophic factor. J. Cereb. Blood Flow Metab., 1998, 18, 345-348.
32. Tsuzuki, N.; Miyazawa, T.; Matsumoto, K.; Nakamura, T.; Shima, K. Hepatocyte growth factor reduces the infarct volume after transient focal cerebral ischemia in rats. Neurol. Res., 2001, 23, 417-424.
33. Sun, Y.; Jin, K.; Xie, L.; Childs, J.; Mao, X.O.; Logvinova, A. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest., 2003, 111, 1843-1851.
34. Zhang, Z.G.; Zhang, L.; Jiang, Q.; Zhang, R.; Davies, K.; Powers, C. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J. Clin. Invest., 2000, 106, 829-838.
35. Uematsu, Y.; Fujise, N.; Kohsaka, K.; Masunaga, H.; Higashio, K. Effective administration route for the deleted form of hepatocyte growth factor To exert its pharmacological effects. J. Pharm. Sci., 1999, 88, 131-135.
36. Shimamura, M.; Sato, N.; Oshima, K.; Aoki, M.; Kurinami, H.; Waguri, S. Novel therapeutic strategy to treat brain ischemia: overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model. Circulation, 2004, 109, 424-431.
37. Shimamura, M.; Sato, N.; Waguri, S.; Uchiyama, Y.; Hayashi, T.; Iida, H. Gene transfer of hepatocyte growth factor gene improves learning and memory in the chronic stage of cerebral infarction. Hypertension, 2006, 47, 742-751.
38. Li, J.; Lu, Z.; Li, W.L.; Yu, S.P.; Wei, L. Cell death and proliferation in NF-kappaB p50 knockout mouse after cerebral ischemia. Brain Res., 2008, 1230, 281-289.
39. Duckworth, E.A.; Butler, T.; Collier, L.; Collier, S.; Pennypacker, K. R. NF-kappaB protects neurons from ischemic injury after middle cerebral artery occlusion in mice. Brain Res., 2006, 1088, 167-175.
40. Harari, O.A.; Liao, J.K. NF-kappaB and innate immunity in ischemic stroke. Ann. N. Y. Acad. Sci., 1207, 32-40.
41. Li, T.; Tachibana, K.; Kuroki, M. Gene transfer with echoenhanced contrast agents: comparison between Albunex, Optison, and Levovist in mice--initial results. Radiology, 2003, 229, 423-428.
42. Shimamura, M.; Sato, N.; Taniyama, Y.; Kurinami, H.; Tanaka, H.; Takami, T. Gene transfer into adult rat spinal cord using naked plasmid DNA and ultrasound microbubbles. J. Gene Med., 2005, 7, 1468-1474.
43. Endoh, M.; Koibuchi, N.; Sato, M.; Morishita, R.; Kanzaki, T.; Murata, Y. Fetal gene transfer by intrauterine injection with micro- bubble-enhanced ultrasound. Mol. Ther., 2002, 5, 501-508.
44. Taniyama, Y.; Tachibana, K.; Hiraoka, K.; Aoki, M.; Yamamoto, S.; Matsumoto, K. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther., 2002, 9, 372-380.
45. Juffermans, L.J.; Dijkmans, P.A.; Musters, R.J.; Visser, C.A.; Kamp, O. Transient permeabilization of cell membranes by ultra- sound-exposed microbubbles is related to formation of hydrogen peroxide. Am. J. Physiol. Heart Circ. Physiol., 2006, 291, H1595-1601.
46. Azuma, H.; Tomita, N.; Kaneda, Y.; Koike, H.; Ogihara, T.; Katsuoka, Y. Transfection of NFkappaB-decoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts. Gene Ther., 2003, 10, 415-425.
47. Azuma, H.; Tomita, N.; Sakamoto, T.; Kiyama, S.; Inamoto, T.; Takahara, K. Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int. J. Cancer, 2008, 122, 1645-1656.
48. Takeuchi, D., Sato, N.; Shimamura, M.; Kurinami, H.; Takeda, S.; Shinohara, M. Alleviation of Abeta-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther., 2008, 15, 561-571.
49. Mannes, A.J.; Caudle, R.M.; O'Connell, B.C.; Iadarola, M.J. Adenoviral gene transfer to spinal-cord neurons: intrathecal vs. intraparenchymal administration. Brain Res., 1998, 793, 1-6.
50. Chen, S.; Shohet, R.V.; Bekeredjian, R.; Frenkel, P.; Grayburn, P.A. Optimization of ultrasound parameters for cardiac gene delivery of adenoviral or plasmid deoxyribonucleic acid by ultrasoundtargeted microbubble destruction. J. Am. Coll. Cardiol., 2003, 42, 301-308.
51. Alter, J.; Sennoga, C.A.; Lopes, D.M.; Eckersley, R.J.; Wells, D.J. Microbubble stability is a major determinant of the efficiency of ultrasound and microbubble mediated in vivo gene transfer. Ultrasound Med. Biol., 2009, 35, 976-984.
52. Cui, Z.; Baizer, L.; Mumper, R.J. Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. J. Biotechnol., 2003, 102, 105-115.
53. Mitragotri, S. Current status and future prospects of needle-free liquid jet injectors. Nat. Rev. Drug Discov., 2006, 5, 543-548.
54. Choi, A.H.; Smiley, K.; Basu, M.; McNeal, M.M.; Shao, M.; Bean, J.A. Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection. Vaccine, 2007, 25, 3215-3218.
55. Hallermalm, K.; Johansson, S.; Brave, A.; Ek, M.; Engstrom, G.; Boberg, A. Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer. Scand. J. Immunol., 2007, 66, 43-51.
56. Soboll, G.; Hussey, S.B.; Whalley, J.M.; Allen, G.P.; Koen, M.T.; Santucci, N. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies. Vet. Immunol. Immunopathol., 2006, 111, 81-95.
57. Degano, P.; Sarphie, D.F.; Bangham, C.R. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system. Vaccine, 1998, 16, 394-398.
58. Tacket, C.O.; Roy, M.J.; Widera, G.; Swain, W.F.; Broome, S.; Edelman, R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine, 1999, 17, 2826-2829.
59. Breathnach, C.C.; Rudersdorf, R.; Lunn, D.P. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Vet. Immunol. Immunopathol., 2004, 98, 127-136.
60. Kunugiza, Y.; Tomita, N.; Taniyama, Y.; Tomita, T.; Osako, M.K.; Tamai, K. Acceleration of wound healing by combined gene transfer of hepatocyte growth factor and prostacyclin synthase with Shima Jet. Gene Ther., 2006; 13, 1143-1152.
61. Sawamura, D.; Ina, S.; Itai, K.; Meng, X.; Kon, A.; Tamai, K. In vivo gene introduction into keratinocytes using jet injection. Gene Ther., 1999, 6, 1785-1787.
62. Nakagawa, A.; Makino, H.; Aoki, M.; Miyake, T.; Shiraya, S.; Nakamura, T. Improvement of survival of skin flaps by combined gene transfer of hepatocyte growth factor and prostacyclin synthase. J. Gene Med., 2007, 9, 1087-1094.
63. Walther, W.; Stein, U.; Fichtner, I.; Malcherek, L.; Lemm, M.; Schlag, P.M. Nonviral in vivo gene delivery into tumors using a novel low volume jet-injection technology. Gene Ther., 2001, 8, 173-180.
64. Walther, W.; Stein, U.; Fichtner, I.; Schlag, P.M. Low-volume jet injection for efficient nonviral in vivo gene transfer. Mol. Biotechnol., 2004, 28, 121-128.
65. Walther, W.; Siegel, R.; Kobelt, D.; Knosel, T.; Dietel, M.; Bembenek, A. Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer. Clin. Cancer Res., 2008, 14, 7545-7553.
66. Hemmi, H.; Takeuchi, O.; Kawai, T.; Kaisho, T.; Sato, S.; Sanjo, H. A Toll-like receptor recognizes bacterial DNA. Nature, 2000, 408, 740-745.
67. Pertmer, T.M.; Eisenbraun, M.D.; McCabe, D.; Prayaga, S.K.; Fuller, D.H.; Haynes, J.R. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine, 1995, 13, 1427-1430.
68. Kutzler, M.A.; Weiner, D.B. DNA vaccines: ready for prime time? Nat. Rev. Genet., 2008, 9, 776-788.
69. Davis, H.L.; Michel, M.L.; Mancini, M.; Schleef, M.; Whalen, R.G. Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Vaccine, 1994, 12, 1503-1509.
70. Brave, A.; Boberg, A.; Gudmundsdotter, L.; Rollman, E.; Hallermalm, K.; Ljungberg, K. A new multi-clade DNA prime/ recombinant MVA boost vaccine induces broad and high levels of HIV-1specific CD8(+) T-cell and humoral responses in mice. Mol. Ther., 2007, 15, 1724-1733.
71. Cattamanchi, A.; Posavad, C.M.; Wald, A.; Baine, Y.; Moses, J.; Higgins, T.J. Phase I study of a herpes simplex virus type 2 (HSV2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin. Vaccine Immunol., 2008, 15, 1638-1643.
72. Haensler, J.; Verdelet, C.; Sanchez, V.; Girerd-Chambaz, Y.; Bonnin, A.; Trannoy, E. Intradermal DNA immunization by using jetinjectors in mice and monkeys. Vaccine, 1999, 17, 628-638.
73. Brave, A.; Ljungberg, K.; Boberg, A.; Rollman, E.; Isaguliants, M.; Lundgren, B. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol. Ther., 2005, 12, 1197-1205.
74. Nicoll, J.A.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H.; Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med., 2003, 9, 448-452.
75. Monsonego, A.; Zota, V.; Karni, A.; Krieger, J.I.; Bar-Or, A.; Bitan, G. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest., 2003, 112, 415-422.
76. Lambracht-Washington, D.; Qu, B.X.; Fu, M.; Eagar, T.N.; Stuve, O.; Rosenberg, R.N. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA, 2009, 302, 1796-802.
77. Ferrera, F.; La Cava, A.; Rizzi, M.; Hahn, B.H.; Indiveri, F.; Filaci, G. Gene vaccination for the induction of immune tolerance. Ann. N. Y. Acad. Sci., 2007, 1110, 99-111.
78. Selmaj, K.; Kowal, C.; Walczak, A.; Nowicka, J.; Raine, C.S. Naked DNA vaccination differentially modulates autoimmune responses in experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2000, 111, 34-44.
79. Walczak, A.; Szymanska, B.; Selmaj, K. Differential prevention of experimental autoimmune encephalomyelitis with antigen-specific DNA vaccination. Clin. Neurol. Neurosurg., 2004, 106, 241-245.
80. Bar-Or, A.; Vollmer, T.; Antel, J.; Arnold, D.L.; Bodner, C.A.; Campagnolo, D. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch. Neurol., 2007, 64, 1407-1415.
81. Garren, H.; Robinson, W.H.; Krasulova, E.; Havrdova, E.; Nadj, C.; Selmaj, K. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann. Neurol., 2008, 63, 611-620.
82. Rivest, V.; Phivilay, A.; Julien, C.; Belanger, S.; Tremblay, C.; Emond, V. Novel liposomal formulation for targeted gene delivery. Pharm. Res., 2007, 24, 981-990.
83. Zhu, C.; Zhang, Y.; Zhang, Y.F.; Yi Li, J.; Boado, R.J.; Pardridge, W.M. Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. J. Gene Med., 2004, 6, 906-912.